Trident Lifeline
262.85
+6.80(+2.66%)
Market Cap₹313.61 Cr
PE Ratio16.37
IndustryHealthcare
Company Performance:
1D+2.66%
1M-13.82%
6M-6.12%
1Y+10.79%
5Y+143.04%
View Company Insightsright
More news about Trident Lifeline
12Nov 25
Trident Lifeline Reports 52% Jump in Half-Year Revenue, Consolidated Profit Rises 49%
Trident Lifeline Limited (TLL) announced robust financial results for the half year ended September 30, 2025. The company's consolidated revenue surged 82% year-over-year to ₹5,335.68 crores. Net profit increased by 49% to ₹801.13 crores, while EPS improved by 47% to ₹6.91. TLL's standalone revenue rose 52% to ₹4,625.86 crores, with net profit up 31% to ₹841.71 crores. The company's strong performance is attributed to its diversified business model and strategic acquisitions across multiple subsidiaries in the pharmaceutical and healthcare sectors.
 no imag found
30Jul 25
Trident Lifeline Reports 27% Revenue Growth in Q1FY26
Trident Lifeline Limited reported robust Q1FY26 financial results. Revenue increased by 27% to ₹1,935.48 lakh, EBITDA grew 20% to ₹546.36 lakh, and profit after tax rose 15% to ₹347.59 lakh. The company operates in 43 countries with 1,035 registered export products and 2,329 in process. Trident maintains a diverse product portfolio of 3,364 items across various therapeutic categories. Management expressed satisfaction with the performance and anticipates continued growth driven by organic and inorganic expansion strategies.
 no imag found
28Jul 25
Trident Lifeline Reports Robust Q1 Results, Appoints New Secretarial Auditor
Trident Lifeline Limited announced its Q1 financial results, showing strong performance. Standalone net sales were Rs 2,084.65 lacs with a net profit of Rs 347.59 lacs. Consolidated net sales reached Rs 3,401.07 lacs with a net profit of Rs 306.28 lacs. The Board approved the appointment of M/s. Amareliya & Associates as Secretarial Auditor for five years, subject to shareholder approval. No investor complaints were pending during the quarter.
 no imag found
16Apr 25
Trident Lifeline Approves Issue of Convertible Warrants, Plans to Raise Up to ₹26.57 Crore
Trident Lifeline's Board of Directors has approved the issuance of 9,99,000 fully convertible warrants at ₹266 each, potentially raising ₹26.57 crore. The warrants are convertible into equity shares within 18 months of allotment. The company also plans to increase its Authorized Share Capital from ₹12 crore to ₹15 crore, subject to shareholder approval. An EGM is scheduled for May 9, 2025, to seek necessary approvals.
 no imag found
09Apr 25
Trident Lifeline to Consider Fund Raising and Share Capital Increase in Upcoming Board Meeting
Trident Lifeline Limited has scheduled a board meeting for April 16, 2025, to discuss and potentially approve significant financial initiatives. The agenda includes increasing authorized share capital, issuing equity shares or convertible warrants on a preferential basis, and setting up an Extra-Ordinary General Meeting (EGM) for shareholder approval. The company has closed the trading window for insiders from April 1, 2025, until 48 hours after the declaration of audited financial results for the quarter and year ended March 31, 2025.
 no imag found
Trident Lifeline
262.85
+6.80
(+2.66%)
1 Year Returns:+10.79%
Industry Peers
Sun Pharmaceutical
1,724.40
(+0.64%)
Divis Laboratories
6,291.00
(-0.10%)
Torrent Pharmaceuticals
4,241.70
(+0.36%)
Cipla
1,341.10
(+0.92%)
Dr Reddys Laboratories
1,280.40
(-0.15%)
Lupin
2,219.40
(-0.42%)
Zydus Life Science
900.75
(-0.18%)
Mankind Pharma
2,024.30
(-0.75%)
Aurobindo Pharma
1,158.80
(-1.08%)
Alkem Laboratories
5,392.00
(+0.28%)